Item 8.01 Other Events.
On May 15, 2020, Blueprint Medicines Corporation issued a press release
announcing that the U.S. Food and Drug Administration has issued a complete
response letter for the new drug application of avapritinib for the treatment of
adults with unresectable or metastatic fourth-line gastrointestinal stromal
tumor. A copy of the press release is filed herewith as Exhibit 99.1 to this
Current Report on Form 8-K and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press release issued by Blueprint Medicines Corporation on May
15, 2020
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
2
© Edgar Online, source Glimpses